GenQual develops companion diagnostics to improve treatment outcomes for autoimmune and oncology diseases.
GenQual develops companion diagnostics to stratify responders from non-responders and to determine appropriate dosage for very expensive drug therapies.
Our proof-of-concept stage diagnostics are designed as companion products for IL-6 and TNF-a mAb, and related biologics. We will sell our diagnostic kits to drug developers and CLIA laboratories. GenQual is ~70% subscribed in our current $250,000 Series AA Preferred funding round (7/2014)